Prevention of hyperphosphatemia in kidney disorder patients
DC
First Claim
Patent Images
1. A method of treating a patient having renal osteodystrophy while avoiding hyperphosphatemia comprising administering to said patient a vitamin D compound that has minimal effect on blood serum phosphorus of said patient, said vitamin D compound selected from a 19-nor-vitamin D2 compound having the formula:
- ##STR5## where X1 and X2 each represent, independently, hydrogen or a hydroxy-protecting group; and
where R1 is selected from hydrogen, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C1-5 -- alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent; and
where each of R2, R3, and R.sup. 4, independently, is selected from hydrogen, fluoro, trifluoromethyl and C1-5 alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent; and
where R1 and R2, taken together represent an oxo group, or an alkylidene group, ═
CR2 R3, or the group --(CH2)p --, where p is an integer from 2 to 5; and
where R3 and R4, taken together, present an oxo group, or a group --(CH2)q --, where q is an integer from 2 to 5; and
where R5 represents hydrogen, hydroxy, protected hydroxy, or C1-5 alkyl.
4 Assignments
Litigations
0 Petitions
Accused Products
Abstract
The 19-nor-vitamin D analogs, and particularly 19-nor-1α,25-dihydroxyvitamin D2, possess low calcemic and phosphatemic activity while also having the ability to suppress parathyroid hormone (PTH) production. The suppressive effect on PTH secretion of these 19-nor analogs without significant changes in serum calcium or serum phosphorus make them ideal tools for the treatment of secondary hyperparathyroidism in patients having kidney disorders.
18 Citations
11 Claims
-
1. A method of treating a patient having renal osteodystrophy while avoiding hyperphosphatemia comprising administering to said patient a vitamin D compound that has minimal effect on blood serum phosphorus of said patient, said vitamin D compound selected from a 19-nor-vitamin D2 compound having the formula:
- ##STR5## where X1 and X2 each represent, independently, hydrogen or a hydroxy-protecting group; and
where R1 is selected from hydrogen, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C1-5 -- alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent; and
where each of R2, R3, and R.sup. 4, independently, is selected from hydrogen, fluoro, trifluoromethyl and C1-5 alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent; and
where R1 and R2, taken together represent an oxo group, or an alkylidene group, ═
CR2 R3, or the group --(CH2)p --, where p is an integer from 2 to 5; and
where R3 and R4, taken together, present an oxo group, or a group --(CH2)q --, where q is an integer from 2 to 5; and
where R5 represents hydrogen, hydroxy, protected hydroxy, or C1-5 alkyl. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
- ##STR5## where X1 and X2 each represent, independently, hydrogen or a hydroxy-protecting group; and
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
Litigation Data
-
Current AssigneeWisconsin Alumni Research Foundation (University of Wisconsin System), Washington University In St Louis
-
Original AssigneeWisconsin Alumni Research Foundation (University of Wisconsin System)
-
InventorsSlatopolsky, Eduardo, Deluca, Hector F.
-
Primary Examiner(s)Spivack, Phyllis G.
-
Application NumberUS08/502,288Time in Patent Office565 DaysField of Search514/167US Class Current514/167CPC Class CodesA61K 31/592 9,10-Secoergostane derivati...A61K 31/593 9,10-Secocholestane derivat...A61P 13/02 of urine or of the urinary ...A61P 15/00 Drugs for genital or sexual...A61P 3/02 Nutrients, e.g. vitamins, m...A61P 3/14 for calcium homeostasis vit...
